Does synthetic biology hold the key to unlocking solid tumors for cell and gene therapy?
Cell & Gene Therapy Insights 2023; 9(7), 947–953
10.18609/cgti.2023.120
Published: 20 August
Interview
Ming-Ru Wu
While cellular immunotherapy holds promise in treating liquid and potentially solid tumors, considerable challenges prevent these therapies from being wholly effective. David McCall, Senior Editor at BioInsights, speaks withMing-Ru Wu, Assistant Professor, Dana-Farber Cancer Institute and Harvard Medical School, about his work in employing synthetic biology principles, AI, high-throughput screening, and multiomics tools to design a new wave of immunotherapies with the potential to advance the field into the mainstream of cancer therapy.
